Calithera Biosciences, Inc. (NASDAQ:CALA – Get Rating) Director Deepika Pakianathan sold 121,333 shares of the firm's stock in a transaction dated Friday, January 27th. The shares were sold at an average price of $0.39, for a total value of $47,319.87. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.
Calithera Biosciences Price Performance
NASDAQ CALA opened at $0.37 on Thursday. The firm has a market cap of $1.78 million, a P/E ratio of -0.01 and a beta of 1.31. The stock's 50-day moving average is $1.65 and its 200-day moving average is $2.63. Calithera Biosciences, Inc. has a one year low of $0.30 and a one year high of $13.38.
Get Calithera Biosciences alerts:Calithera Biosciences (NASDAQ:CALA – Get Rating) last released its quarterly earnings results on Monday, November 14th. The biotechnology company reported ($2.01) EPS for the quarter, missing analysts' consensus estimates of ($1.99) by ($0.02). Equities analysts anticipate that Calithera Biosciences, Inc. will post -8.62 EPS for the current year.
Institutional Investors Weigh In On Calithera Biosciences
Hedge funds have recently modified their holdings of the business. Renaissance Technologies LLC raised its position in Calithera Biosciences by 36.5% in the 1st quarter. Renaissance Technologies LLC now owns 1,853,500 shares of the biotechnology company's stock valued at $749,000 after buying an additional 496,100 shares during the last quarter. Vanguard Group Inc. raised its position in Calithera Biosciences by 23.4% in the 3rd quarter. Vanguard Group Inc. now owns 141,217 shares of the biotechnology company's stock valued at $415,000 after buying an additional 26,800 shares during the last quarter. Alyeska Investment Group L.P. acquired a new stake in Calithera Biosciences in the 1st quarter valued at approximately $404,000. Affinity Asset Advisors LLC acquired a new stake in Calithera Biosciences in the 1st quarter valued at approximately $404,000. Finally, Goldman Sachs Group Inc. raised its position in Calithera Biosciences by 143.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 123,739 shares of the biotechnology company's stock valued at $50,000 after buying an additional 72,865 shares during the last quarter. Institutional investors and hedge funds own 33.73% of the company's stock.Analyst Upgrades and Downgrades
Several equities analysts have weighed in on the company. LADENBURG THALM/SH SH lowered Calithera Biosciences from a "buy" rating to a "neutral" rating in a research note on Tuesday, November 15th. SVB Leerink lowered Calithera Biosciences from an "outperform" rating to a "market perform" rating in a research note on Tuesday, November 15th. Finally, StockNews.com assumed coverage on Calithera Biosciences in a research note on Monday. They issued a "hold" rating on the stock.
Calithera Biosciences Company Profile
(Get Rating)
Calithera Biosciences, Inc is a clinical-stage biopharmaceutical company, which focuses on discovering and developing small molecule drugs that target novel and critical metabolic pathways in tumor and cancer-fighting immune cells. It offers programs such as Pipeline, Glutaminase Inhibitor, and Arginase Inhibitor.
Read More
- Get a free copy of the StockNews.com research report on Calithera Biosciences (CALA)
- Bed Bath & Beyond Is Circling the Drain
- Allegro Microsystems Is A Well-Positioned Semiconductor Stock
- Scotts Miracle-Gro Hits Bottom, Reversal In Play
- Altria is a Great Recession Stock, Long-Term Outlook Uncertain
- Novavax Shares Jumped in January While Others Slipped
Receive News & Ratings for Calithera Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.